Compare
Olema Pharmaceuticals, Inc. vs Dianthus Therapeutics, Inc. vs Syndax Pharmaceuticals Inc vs Edgewise Therapeutics, Inc.
| Latest fiscal year | Olema Pharmaceuticals, Inc. OLMA | Dianthus Therapeutics, Inc. DNTH | Syndax Pharmaceuticals Inc SNDX | Edgewise Therapeutics, Inc. EWTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $2.04M | $172.35M | n/a |
| Revenue growth (YoY) | n/a | -67.3% | +627.8% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | -158.4% | n/a |
| Net margin | n/a | n/m | -165.6% | n/a |
| Net income | -$162.45M | -$162.34M | -$285.42M | -$167.79M |
| EPS (Diluted) | -$1.87 | -$4.20 | -$3.29 | -$1.63 |
| Operating cash flow | -$146.72M | -$129.06M | -$322.98M | -$143.82M |
| Free cash flow | n/a | n/a | -$323.17M | -$144.07M |
| Cash & equivalents | $48.30M | $51.09M | $134.93M | $61.15M |
| Total assets | $533.43M | $530.92M | $529.71M | $552.60M |
| Total liabilities | $54.87M | $37.52M | $465.08M | $30.35M |
| Shareholders' equity | $478.56M | $493.40M | $64.63M | $522.26M |
| Return on year-end equity | -33.9% | -32.9% | -441.6% | -32.1% |
| Shares outstanding | 81.38M | 43.22M | 87.41M | 106.25M |
Revenue, most recent five fiscal years
| Fiscal year | Olema Pharmaceuticals, Inc. | Dianthus Therapeutics, Inc. | Syndax Pharmaceuticals Inc | Edgewise Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $2.04M Ended 2025-12-31 | $172.35M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $6.24M Ended 2024-12-31 | $23.68M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $2.83M Ended 2023-12-31 | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $139.71M Ended 2021-12-31 | n/a |